| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/07/2006 | US20060199781 Assays based on BTF3 activity |
| 09/07/2006 | US20060199773 Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt |
| 09/07/2006 | US20060199772 Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy |
| 09/07/2006 | US20060199771 Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
| 09/07/2006 | US20060199770 Functionalized carbon nanotubes, a process for preparing the same and their use in medicinal chemistry |
| 09/07/2006 | US20060199769 Alpha-fetoprotein peptides and uses thereof |
| 09/07/2006 | US20060199768 Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens |
| 09/07/2006 | US20060199767 Contacting cardiac muscle cells with a neuregulin protein to activate the MAP kinase pathway in cardiac muscle cells and induce remodeling of cardiac muscle cell sarcomeric and cytoskeleton structures or cell-cell adhesions |
| 09/07/2006 | US20060199766 Pharmaceutical composition comprising a factor VIIa and a factor XIII |
| 09/07/2006 | US20060199764 FGF growth factor analogs |
| 09/07/2006 | US20060199763 Derivatives of GLP-1 analogs |
| 09/07/2006 | US20060199762 Skin ulcer preventive curative agent containing human recombinant hgf |
| 09/07/2006 | US20060199761 Insulin resistance improving agent |
| 09/07/2006 | US20060199760 Methods for the therapeutic use of cyclosporine components |
| 09/07/2006 | US20060199759 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| 09/07/2006 | US20060199758 Prepared by reacting a cellulose, starch, or glycogen surface such as wood or cotton with a quaternary ammonium salt of 1,4-diazoniabicyclo [2.2.2]octane |
| 09/07/2006 | US20060199248 Q3 SPARC deletion mutant and uses thereof |
| 09/07/2006 | US20060199195 Nucleic acid encoding Schwannomin-Binding-Proteins and products related thereto |
| 09/07/2006 | US20060199181 Compositions and methods for the treatment of immune related diseases |
| 09/07/2006 | US20060199180 Compositions and methods relating to ovarian specific genes and proteins |
| 09/07/2006 | US20060199179 Method for diagnosis of colorectal tumors |
| 09/07/2006 | US20060199177 T helper cell epitopes |
| 09/07/2006 | US20060198939 Porous ceramic composite bone grafts |
| 09/07/2006 | US20060198894 Stabilized, solid-state polypeptide particles |
| 09/07/2006 | US20060198889 Roflumilast and integrin inhibitor combination and treatement method |
| 09/07/2006 | US20060198886 Medicament having coated methenamine combined with acidifier |
| 09/07/2006 | US20060198871 Methods for treating neovascularization and intravitreal implants |
| 09/07/2006 | US20060198869 Bioabsorable medical devices |
| 09/07/2006 | US20060198863 Formable composition; tricalcium phosphate particles in hydrogel carrier; aqueous solution contqining citric acid buffer; controlling particle size |
| 09/07/2006 | US20060198855 Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| 09/07/2006 | US20060198844 Determining amount of the BMP-2/BMP-2 receptor complex in the formed in the presence of test agent;identifying a candidate agent for for use in reducing vascularization in non-small cell lung tumors if amount of complex formed in presence of test agent is lower than amount formed in absence of compound |
| 09/07/2006 | US20060198842 treating skeletal muscle atrophy with a corticotropin releasing factor 2 receptor (CRF2R) agonist such as Sauvagine, urocortin II or an antibody |
| 09/07/2006 | US20060198841 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 09/07/2006 | US20060198840 increased in vivo half-lives due to the presence of an immunoglobulin G (IgG) constant domain; pharmacokinetics; diagnosis or immunotherapy; antibody conjugates; palivizumab |
| 09/07/2006 | US20060198839 Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
| 09/07/2006 | US20060198838 Combination enzyme for cystic fibrosis |
| 09/07/2006 | US20060198837 Coagulation and fibrinolytic cascades modulator |
| 09/07/2006 | US20060198836 Method of treating hit patients with argatroban |
| 09/07/2006 | US20060198835 Nucleic acid molecules encoding osteogenic proteins |
| 09/07/2006 | US20060198834 Method of administration of cpn10 to a donor and/or recipient animal or cells, tissues or organs derived from the donor; in a particularly advantageous form treatment of both the donor and recipient animal; treatment and/or prevention of graft versus host disease |
| 09/07/2006 | US20060198833 Compositions and methods for targeting a polypeptide to the central nervous system |
| 09/07/2006 | US20060198832 Peptide drugs for chronic lymphocytic leukemia (CLL) and other cancers |
| 09/07/2006 | US20060198831 Nitrosylation of protein SH groups and amino acid residues as a therapeutic modality |
| 09/07/2006 | US20060198830 Ubiquinone composition and a container for its convenient transport and storage |
| 09/07/2006 | US20060198826 Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof |
| 09/07/2006 | US20060198824 Treatments for flaviviridae virus infection |
| 09/07/2006 | US20060198823 Compositions and methods for treating viral infections |
| 09/07/2006 | US20060198822 Treatment for multiple sclerosis |
| 09/07/2006 | US20060198821 administering to said individual an effective amount of either i) recombinant protein CD73 or ii) a cytokine or another factor-being capable of inducing endothelial CD73 expression; inflammation |
| 09/07/2006 | US20060198820 Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| 09/07/2006 | US20060198819 Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
| 09/07/2006 | US20060198815 Pharmaceutical formulations for sustained release |
| 09/07/2006 | US20060198813 Substituted fullerene compositions and their use in treatment of shock |
| 09/07/2006 | US20060198800 Skin care compositions including hexapeptide complexes and methods of their manufacture |
| 09/07/2006 | US20060198787 Biomarkers for predicting liver fibrosis treatment efficacy |
| 09/07/2006 | US20060198784 Methods of treatment using antibodies to Neutrokine-alpha |
| 09/07/2006 | DE102005009784A1 Peptid-Mimetika und ihre Verwendung als Inhibitoren des 20S Proteasoms, 26S Proteasoms und Immunoproteasoms Peptide mimetics and their use as inhibitors of the 20S proteasome, the 26S proteasome and immunoproteasome |
| 09/07/2006 | DE102005008416A1 Verfahren zur Reinigung von marinem Kollagen sowie dessen Verarbeitung zu porösen Schwämmen A method for purifying marine collagen and the processing of porous sponges |
| 09/07/2006 | CA2496637A1 Treatment of inflammatory conditions of the intestine using high density lipoprotein |
| 09/06/2006 | EP1698701A1 Use of MHC class II ligands as adjuvant for vaccination and lag-3 in cancer treatment |
| 09/06/2006 | EP1698697A2 SSD-containing protein, process for producing the same and use thereof |
| 09/06/2006 | EP1698695A2 Antisense oligonucleotides for the inhibition of expression of type I procollagen |
| 09/06/2006 | EP1698693A1 Royal jelly peptide and composition containing the same |
| 09/06/2006 | EP1698691A1 Growth factor mutants with improved biological activity |
| 09/06/2006 | EP1698639A2 Pluripotency determining factors and uses thereof |
| 09/06/2006 | EP1698638A1 Lipopeptides having pharmaceutical activity |
| 09/06/2006 | EP1698636A1 Preparation of derivatized peptides from bile acids |
| 09/06/2006 | EP1698629A2 Polyamines and their use in therapy |
| 09/06/2006 | EP1698347A2 hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination |
| 09/06/2006 | EP1698346A1 Agent against malignant neuroglia and agent against malignant neuroglia for animals |
| 09/06/2006 | EP1698345A2 Peptide antagonists of zonulin and methods for use of the same |
| 09/06/2006 | EP1697751A2 Assay and treatment |
| 09/06/2006 | EP1697542A2 Compositions and methods of using apoptosis signaling kinase related kinase (askrk) |
| 09/06/2006 | EP1697517A1 Brachyspira pilosicoli 72kda outer-membrane protein and diagnostic and therapeutic uses thereof |
| 09/06/2006 | EP1697501A2 Method for in vitro differentiation of neuronal stem cells or cells derived from neuronal stem cells |
| 09/06/2006 | EP1697498A2 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis |
| 09/06/2006 | EP1697418A2 Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation |
| 09/06/2006 | EP1697413A2 Human lxr alpha variants |
| 09/06/2006 | EP1697409A1 Secreted neural apoptosis inhibiting proteins |
| 09/06/2006 | EP1697408A2 Tumor antigens, and use thereof |
| 09/06/2006 | EP1697407A2 Regulation involving abin-2 |
| 09/06/2006 | EP1697403A2 Haemophilus influenzae type iv pili |
| 09/06/2006 | EP1697401A1 Tetrapeptide regulating blood glucose level in diabetes mellitus |
| 09/06/2006 | EP1697400A1 Biphenyl-substituted antibacterial macrocycles |
| 09/06/2006 | EP1696962A2 Novel glp-1 analogues linked to albumin-like agents |
| 09/06/2006 | EP1696960A1 Intranasal administration of glucose-regulating peptides |
| 09/06/2006 | EP1696949A2 Vegf receptor antagonists |
| 09/06/2006 | EP1696948A1 Use of relaxin as adjuvant in the differentiation of stem cells for the reconstruction of tissues |
| 09/06/2006 | EP1696947A1 Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases |
| 09/06/2006 | EP1696946A1 Use of interferon tau for the treatment of obesity and for promotion of weight loss |
| 09/06/2006 | EP1696945A1 Self-assembling peptide amphiphiles and related methods for growth factor delivery |
| 09/06/2006 | EP1696944A2 Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof |
| 09/06/2006 | EP1696943A2 Diastereomeric peptides useful as inhibitors of membrane protein assembly |
| 09/06/2006 | EP1696942A1 Pharmaceutical product comprising tissue of the male vegetal reproductive system |
| 09/06/2006 | EP1696909A1 Benzothiazole derivatives for the treatment of diabetes |
| 09/06/2006 | EP1696897A1 Compositions and methods for treating diabetes |
| 09/06/2006 | EP1696894A1 Treating infectious diseases using ice inhibitors |
| 09/06/2006 | EP1696888A1 Process for producing pellets for pharmaceutical compositions |
| 09/06/2006 | EP1608351B1 Compositions containing superoxide dismutase and a selected et 5-lipoxygenase inhibitor and uses thereof |
| 09/06/2006 | EP1497317B1 Dipeptidic growth hormone secretagogues |